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Background: Although dual-boosted protease inhibitors regimen is not recommended in children with HIV
infection, such a strategy could be useful in subjects with a complex resistance profile. This study was aimed at
assessing the long term efficacy and safety of a double-boosted protease inhibitor combination, fosamprenavir
(fAVP) and atazanavir/ritonavir (ATV/r) in a cohort of HIV-infected children and adolescents who had failed with
nucleoside reverse transcriptase inhibitors.
Methods: Seven vertically infected children and adolescents who had previously failed highly active antiretroviral
therapy and were resistant to nucleoside reverse transcriptase inhibitors, received a dual protease inhibitor (PI)
regimen including fAVP plus ATV/r for 42 months. The patients were assessed at baseline, every month for the first
24 weeks of therapy and every 3 months until month 32. Physical examination, CD4+ cell count, HIV-RNA viral load,
lipid profile and hepatic function were assessed throughout the follow up.
Results: During the study no serious adverse events were reported. CD4 absolute number increased over-time in all
subjects. At baseline the median HIV-RNA was 6562 cp/mL (ranging 1048 -102772 cp/mL) and rapidly decreased
below the limit of detection (50 cp/mL) after 2 months of the new treatment and remained undetectable in all
cases through the entire study period. At the beginning of the study all cases showed a normal lipid profile. During
the study period, 4/7 subjects showed total cholesterol, low density lipoprotein and triglyceride levels >97th cent.le
for the males and 94th cent.le for the females. HDL cholesterol showed protective values. Hepatic enzymes
remained stable during the entire observation, whereas total bilirubin showed toxicity II/III grade in 6/7 subjects. No
change in fat redistribution and insulin resistance was observed.
Conclusion: Dual-boosted protease inhibitor therapy was virologically and immunologically effective and it could
be considered as a possible alternative to a rescue regimen in children and adolescents. However,
hypercholesterolemia and hypertriglyceridemia need close follow-up and may limit the use of this therapeutic
option.* Correspondence: stefano.rusconi@unimi.it
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The introduction of potent combination antiretroviral
(ARV) therapy has been found to improve disease progres-
sion and prolonged survival in HIV-infected adults and
children [1-3]. Despite the clinical favourable outcome
observed with ARV, it is difficult to choose an effective al-
ternative regimen after multiple therapeutic failures in
many patients. Approximately 40 to 50% of adult patients
receiving ARV regimen containing a protease inhibitor
(PI) experience virologic failure [4,5], mainly due to side
effects and unfavourable pill burden. Moreover the long
term control of viral replication is even lower in paediatric
patients [6]. Most patients show primary mutations to pro-
tease inhibitors (PIs), resistance to non-nucleoside reverse
transcriptase inhibitors (NNRTI) and low activity of nu-
cleoside reverse transcriptase inhibitors (N[n]RTIs). In this
setting, the idea of using a dual-boosted PI regimen with
low-dose boosting ritonavir may be considered.
The rationale of using a dual-boosted PI regimen is to
reach synergistic or additive activity against HIV and to
further increase the genetic barrier to resistance, to ob-
tain high plasma concentrations of both PIs with only
one boost and to avoid toxicity with N(n)RTI-sparing
regimens [7].
The short-term efficacy of double-boosted PI in naïve
adults has been disappointing [8,9], while studies in
treatment experienced patients showed more favourable
results. In an observational cohort study of 128 heavily
pre-treated patients, the combination of lopinavir/ritona-
vir (LPV/r) and saquinavir (SQV) obtained a virological
response (HIV-RNA< 400 copies/ml) at week 48 [10,1].
In a recent randomized study in patients who had failed
NNRTI-based regimen, comparing single-boosted PI
with double- boosted PI, Siripasson et al found an ac-
ceptable virological outcome without differences in the
two groups [11].
In pediatric patients, dual boosted PI regimen is not
recommended because few data are available in this
population [12]. However, two recent studies showed
that dual-boosted SQV and LPV may be an effective and
safe alternative for a second-line regimen in pre-treated
children, nevertheless a close follow up is necessary be-
cause dislipidemia can occur during treatment [13,14].
Therefore, we decided to test this therapeutic option in a
long term observational cohort of 7 HIV-infected
children.
Methods
Our observational study evaluated the immuno-virologic
efficacy and the safety profile of dual boosted PI-based
therapy in a cohort of vertically HIV- infected pediatric
patients who had failed nucleoside N(n)RTI based ther-
apy. Inclusion criteria were: ongoing viral replication,
multiple virological failures using a N(n)RTI-containingregimen, and presence of resistance-associated mutations
to N(n)RTI and NNRTI in the current genotype.
Genotype resistance testing (Siemens Healthcare Diag-
nostics TrugeneW HIV-1, Siemens Healthcare Diagnostics,
1717 Deerfield Road, Deerfield, IL 60015-0778, USA) was
performed in each patient before the introduction of the
dual boosted PI-based regimen. Mutations were defined
according to International AIDS Society-USA Drug Resist-
ance Mutation Group [15]. The interpretation of resist-
ance mutations was done through the Stanford HIV Db,
Genotypic Resistance Interpretation Algorithm, version
6.2.0.
Each patient switched to a dual PI-based regimen
consisting of fosamprenavir (fAVP) and atazanavir
(ATV) boosted ritonavir (RTV) in association with
lamivudine (3TC) and this regimen was maintained
over 42 months. Lamivudine was included in the drug
regimen due to its low viral fitness maintenance in
the presence of M184V mutation. The administration
schedule was fAPV 18 mg/kg bid, ATV 150 mg bid
with the booster of RTV 100 mg bid and 3TC 4 mg/
kg bid. Adherence was assessed through the subject’s
pill count and a self-reported evaluation.
CD4 cell counts, HIV-RNA viral load, serum chem-
istry, fasting lipid levels and clinical assessments were
performed in each patient at baseline (T0), 3 months
after the switch and every six months until month 42.
HIV viral load was assessed by Branched-DNA,
Chiron Diagnostics, Emeryville, CA, USA with a lower
limit of detection < 50 copies/mL; CD4 cell count was
performed using standard flow cytometry. Serum
chemistry and lipid levels were assessed by standard
laboratory methods.
The efficacy endpoint was the achievement of plasma
HIV-RNA< 50 copies cp/mL with stable or increasing
CD4 cell counts through 42 months. Virological failure
was defined as having 2 consecutive HIV-RNA> 50 cp/
mL both during the study period and at the end of the
clinical observation (42 months).
Safety assessments included lipid profiles defined as
changes in total cholesterol (TC), high-density lipo-
protein cholesterol (HDL), low-density lipoprotein
cholesterol (LDL) and triglycerides (TG) as well as
hepatic toxicity: aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), total bilirubin (TB),
gamma glutamyl transferase (γGT). Lipid levels were
defined according to the reference by age and gender
in adolescents [16,17].
Lipodistrophy was annually assessed using a checklist
of standard clinical signs for fat redistribution completed
by the pediatrician for each child [18]. Children were
considered to have fat redistribution if they had one or
more of major clinical signs. A combined subtype of fat
redistribution was defined as showing at least one sign of
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lipohypertrophy.
Homeostatic Model Assessment (HOMA) index was
evaluated in this cohort by an oral glucose tolerance test
(OGTT) during the annual follow up visit to check for
insulin resistance. The HOMA index was calculated as
the product of the fasting plasma insulin level (μU/mL)
and the fasting plasma glucose level (mmol/L), divided
by 22.5. HOMA index cut-offs, from the 5th to the 95th
percentile.
Categorical variables are given as the number or per-
centage of subject with the characteristic of interest. Con-
tinuous variables are reported as median, lower (25th
percentile), and upper quartile (75th percentile). The com-
parison between the baseline and 42 month time-point
was conducted with the Wilcoxon non-parametric test.
The level of statistical significance was set at P <0.05. SPSS
15 for Windows was the statistical software package used
for the analyses (SPSS, Chicago, IL, USA).
A formal approval from the Ethical Committee was
not required. Our institution’s IRB does not require ap-
proval for therapeutic interventions which are part of the
regular clinical practice. The children were started on
this treatment as part of their standard care prescribed
by their physician and no treatment was given for the
purposes of this study.Results
The cases, 5 males and 2 females, showed the following
CDC stage: A1 (1 patient), A2 (1), A3 (1), B3 (2), C2 (1).
The median age of the patients was 15.96 years and the
interquartile range was 10.82 to 18.93 years. One patient
was co-infected with Hepatitis C virus, but his condition
was clinically stable and no laboratory evidence of
decreased hepatic function was evident. All patients pre-
sented the inclusion criteria as previously specified. Prior
to the introduction of the new regimen, 5/7 patients
were taking a N(n)RTI-based antiretroviral regimen and
2/7 an antiretroviral regimen including 2 N(n)RTIs and 1
PI.
The double boosted-PI regimen plus 3TC achieved an
excellent virological and immunological response. As
shown in Figure 1, CD4 absolute number increased over
time in all subjects. At baseline, the median and the
interquartile range for the CD4 absolute number and the
percentage were 364 (217-478)/μL and 18 (16.9-21.2) %,
respectively, whereas at month 42 the values were 618
(534-684)/μL and 26.6 (21.4-28.3) %, respectively. This
increase was statistically significant (p < 0.05).
At baseline the median and HIV-RNA was 6562 cp/ml,
ranging from 1048 to 102772 cp/ mL. Viral load showed a
rapid decrease below the detection limit (50 cp/ mL) after
2 months of the new treatment in all subjects andremained undetectable in all cases throughout of study
period.
The results of the genotype resistance tests are shown
in Table 1. As shown, all pediatric subjects but 1 exhib-
ited resistance to the majority of N(n)RTI and this was
the main reason that promted us to use a dual boosted
PI-based regimen. The only child without resistance
mutations received a dual boosted PI-based regimen due
to hematologic and metabolic toxicities.
Liver enzymes showed a certain degree of variation, but
did not cause any treatment interruption during the study
period. At baseline, the median and range for ALT were
40 (18-78) U/L, whereas they were 33 (30-40) U/L
at month 42. AST resulted 37 (22-70) U/L and 32 (29-38)
U/L and γGT was 27 (18-42) U/L and 28 (18-34) U/L, at
baseline and month 42, respectively. All hepatic enzymes
remained quite stable during the entire observation time
without any statistical difference. As shown in Figure 2,
TB varied more extensively at different time intervals.
Overall one subject maintained a normal level, whereas
the other 4 subjects showed a grade 2. One patient showed
a grade 3 toxicity at month 12, while a single patient
reached the grade 4 of toxicity at month 12, 30 and 42
[17]. At baseline, the TB median and range values were
0.65 (0.30-0.80) mg/dL and reached 3.37 (3.27-3.96) mg/
dL at month 42; this result was statistically significant
(P= 0.046).
Fasting lipid profiles (TC, HDL, LDL, and TG) are
shown in Figure 3. TC showed a significant increase
(p < 0.05) from baseline to month 42, 143 (112-157)
mg/dL and 194 (160-203) mg/dL, respectively. TC values >
97th cent.le for males and 94 thcent.le for females were
detected in 4/7 patients (57%). TG increased from baseline
(78 mg/dL [59-106]) to month 42 (175 mg/dL [135-194])
with a significant difference (P<0.05). TG values >97th per-
centile were detected in 4/7 patients. (57 %) LDL choles-
terol remained stable over-time, with baseline values of 75
(64-105) mg/dl and 106 (92-116) at month 42. LDL
values > 97th cent.le for males and >95th cent.le for females
were detected in patients 4/7 patients (57%). HDL exhib-
ited protective values during the follow up.
At baseline, one out of 7 patients had lipohypertrophy
consisting in truncal fat accumulation, “buffalo hump”
and breast enlargement. In this single patient, lipohyper-
trophy remained stable during the follow up. No other
patients developed signs of lipodistrophy during the
double-boosted PI therapy.
At baseline all patients had a normal HOMA index
(3.8 [1.2-10.1)], which was maintained stable during the
follow up.
Discussion
This study showed that at month 42 a combination regi-
men of fAVP+ATV/r obtained an excellent virological
Figure 1 CD4 cell count profiles in HIV-infected children and adolescents treated with double-boosted protease inhibitors during the
study period.
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good immunological (9% median CD4 increase) outcome
in HIV-infected children and adolescents although there
was an association of a worsening lipid profile. Our results
showed a similar efficacy compared to the other two avail-
able studies of double-boosted PI in experienced HIV-
infected children. These two studies assessed the efficacy
of the combination of SQV and LPV/r in a cohort of 50
HIV-infected children; the first and the second assessment
were performed at week 48 and 96 respectively [13,14].At
week 48 the median CD4 increase was 9% (IQR 5-16) and
the percentage of patients with HIV-RNA<400 and < 50
copies/ml were 78 and 64, respectively. At week 96 the
median CD4 increased by 14% (IQR:7-19) and the per-
centage of patients with HIV-RNA<50 copies/ml was 64.
The dual-PI regimen in our study was chosen due to the
genotypic resistance profile and the ongoing virological
failure. The highly resistant genotypic profile was mainly
due to an extensive exposure to the N(n)RTI class that has
been considered the backbone of antiretroviral regimens.
The presence of NAMs has been demonstrated to be
highly correlated with reduced susceptibility to all N(n)
RTIs [19], thus a therapeutic switch was fully justified.Table 1 Genotypic resistance mutations before switching to a
NNRTI
Patient 98 (G) 103 (R/N) 108 (I) 135 (L/I/V
P1 G L
P2 N I N
P3
P4 No mutations
P5 V V
P6 No mutations
P7 R TMoreover, when this study began, new PIs as tipranavir
and darunavir, the new NNRTI etravirine, and entry inhi-
bitors were not yet available. Raltegravir had not been
licensed even for adult populations. In addition, this dual
boostedPI-based regimen significantly and rapidly
decreased HIV-RNA and led to an improved prognosis
for the patients as well as preventing a worsening of
the genotypic resistance.
The regimen was well tolerated and none of the
patients discontinued the therapy due to side effects.
Hepatic parameters remained stable overtime apart from
TB, as expected. Lipids increased over 36-42 months of
observation without causing therapeutic interruptions.
Hyperlipidemia is a well-know complication of ARV
therapy in pediatric patients. The European Pediatric Lipo-
distrophy Group showed that PI use, specifically ritonavir,
was associated with dyslipidemia [18]. Hypercholesterol-
emia showed a prevalence of 38% in children that took
ritonavir vs 24% in those without ritonavir use. Recently,
Alam et al showed a prevalence of 31% of metabolic ab-
normalities in a cohort of 385 HIV-infected children: 4 out
of 5 of these children had hypertriglyceridemia and 2 out
of 5 of these children had hypercholesterolemia. The usedouble-boosted protease inhibitors regimen
PI Resistant Drugs
) 283 (I)
63 P, 71 V, 77 wt/I, 93 L NVP L-lR
I 10 V, 35 D EFV and NVP L-lR
wt/I 77I none
63 P, 93 L none
35 D, 60 E, 63 P none
No mutations none
10 V, 13 wt/V, 63 P, 77 I none
Figure 2 Total bilirubin profile in HIV-infected children and adolescents treated with double-boosted protease inhibitors during the
study period.
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consistent risk factor for all metabolic abnormality out-
comes [20]. Other two studies showed an association of
the use of a double-PI regimen consisting of LPV/r and
SQV in HIV-infected children with a percentage of
patients with a median serum cholesterol and triglyceride
significantly increased compared to the baseline value.
Similarly, our results showed that almost 57% of children
treated with ATV/r + fAVP developed hypercholesterol-
emia and hypertriglyceridemia. These data may be consid-
ered more serious than those observed in the previous
studies and this could be related to the type of analysis
used. In fact, we did not define dyslipidemia using a single
cut-off value but lipid values were categorized according
to age and gender reference values.
Our study is somehow limited by the small number of
subjects assessed. Since this observation was carried out
in a small number of subjects within the out-patients
clinic, we did not decide to conduct a case-control study.Figure 3 Mean values of lipids (TC, HDL, TG, LDL) in HIV-
infected children and adolescents treated with double-boosted
protease inhibitors during the study period.Moreover, we did not have the possibility to obtain pK
data, thus the relationship between drug exposure and
toxicity could not be assessed. We understand that TDM
studies are of pivotal importance when using drug regi-
mens which include compounds with a potential inter-
action, e.g. 2 PIs.
In this study, we have proposed a therapeutic strategy
that could be considered obsolete and most likely is not
being used in most pediatric Infectious Disesase divi-
sions. Nevertheless, in the presence of multiple failures,
particularly with N (n)RTIs and NNRTIs, this strategy
has overcome the complexity of the resistance pattern.
This double-boosted protease regimen with ATV/r and
fAVP was effective in suppressing HIV viremia and im-
proving immunological outcome. During the study dur-
ation, hypercholesterolmia and hypertriglyceridemia
were commonly observed and need close follow-up. The
impact on bilirubin level and lipid profile suggests cau-
tion in using this regimen in the pediatric population.
Thus, this regimen should only be considered as a pos-
sible option for a rescue treatment in HIV-infected chil-
dren and adolescents who failed N(n)RTIs and more so
in those with an extensive N(n)RTI resistance.Conclusions
The main contribution of this study lies in the clinical ef-
ficacy of a regimen composed by ATV/r and fAVP in ef-
fectively maintaining the viral suppression together with
a good immunological outcome. An increase in lipid
levels was demonstrated in the majority of children
included in our study although none of them discontin-
ued HAART. In the future, safer therapeutic strategies,
with the same effectiveness, will ameliorate the perform-
ance status of our patients. In the meantime, these chil-
dren will be safely followed to that point.
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